周一盘中，康宁杰瑞制药-B（09966）股价大幅上涨，截至发稿时涨幅达8.86%，报10.08港元。该股成交额达1819.5万港元，显示投资者对公司近期发布的中期业绩报告反应积极。
根据公司8月28日发布的2025年上半年业绩报告，康宁杰瑞制药-B实现营收3.19亿元人民币，同比增长84.05%。更值得注意的是，公司扭亏为盈，期内溢利达2157.5万元人民币，而去年同期亏损4489.6万元。每股基本盈利为0.02元人民币，这一转变无疑是推动股价上涨的主要因素。
值得一提的是，公司在研发方面持续加大投入。2025年上半年研发开支达到253.2百万元人民币，较2024年同期的194.5百万元增加了58.7百万元。公司表示，研发开支增加主要由于正在进行的临床试验数目增加、临床研究规模的扩大以及候选药物的临床试验进展。这显示出公司对未来发展的持续投入，有望进一步增强其在医药行业的竞争力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.